MOLNOVA
HIT YOUR RESEARCH TO LEAD

Datasheet (Version 1.0)

Product Name	:	(±)-Zanubrutinib
Synonyms	:	±)-BGB-3111;(±)-BGB 3111;(±)-BGB3111
Cat No.	:	M12460
CAS Number	:	1633350-06-7
Molecular Formula	:	C27H29N5O3
Formula Weight	:	471.55
Chemical Name	:	Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-
Description	:	The active enantiomer of Zanubrutinib (BGB3111), a potent, selective and orally available Btk inhibitor; shows much more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib; demonstrates nanomolar BTK inhibition activity, inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation in several MCL and DLBCL cell lines; demonstrates better anti-tumor activity than ibrutinib in TMD-8 subcutaneous xenograft model.Blood Cancer Phase 3 Clinical
Pathway	:	Tyrosine Kinase
Target	:	BTK
Receptor	:	BTK
Solubility	:	10 mM in DMSO
SMILES	:	NC(C1=C2N(N=C1C3=CC=C(OC4=CC=CC=C4)C=C3)C(C5CCN(C(C=C)=O)CC5)CCN2)=O
Storage	:	(-20℃)
Stability	:	≥ 2 years
Reference	:	



1. Na Li, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor. AACR.

FOR RESEARCH USE ONLY.NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.